ASAnoop Saraya

Anoop Saraya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anoop Saraya has a total of 555 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pathophysiology of sarcopenia in chronic pancreatitis: Insights from muscle biopsy and molecular profiling

    by Neelam Lohani, Sumaira Qamar, Deepika Verma, Srikanth Gopi, Nidhi Singh, Deepak Gunjan, Meher Chanda Sharma, Uma Kanga, S.S. Chauhan, Namrata Singh, et al.

  • Chronic kidney disease in cirrhosis: a study of inpatients from a global perspective

    by Florence Wong, Danielle Adebayo, Jacob George, Ramazan Idilman, Peter C Hayes, Mario R Alvares-Da-Silva, Aldo Torre, Hailemichael Desalgn Mekonnen, Wai-Kay Seto, Shiv Kumar Sarin, et al.

    Background: The prevalence of chronic kidney disease (CKD), defined as a glomerular filtration rate (GFR) of 3 months, is rising in the global population. Objective: To assess the global prevalence of CKD in cirrhosis and how it impacts the prognosis of these patients. Design: The Chronic Liver Disease Evolution and Registry for Events and Decompensation consortium prospectively enrolled non-electively admitted cirrhosis patients from 127 sites globally, each with up to 100 patients. Data collected were demographics, comorbid conditions, cirrhosis history, hospital course and patient outcomes. Patients were divided into those with (CKD+) and without CKD (CKD–) and compared. We also compared patients from different World Bank income strata. Results: Of 7040 inpatients enrolled, the global prevalence of CKD was 18.17%, with the highest prevalence observed in high-income countries (HICs), which paralleled their higher prevalence of metabolic syndrome. CKD+ patients had lower median enrolment GFR (32 (21, 44) mL/min/1.73 m 2 ) when compared with CKD– patients (88 (63, 117) mL/min/1.73 m 2 , p<0.0001), associated with a more complex history of cirrhosis complications, with ascites occurring in 76.5% of CKD+ versus 61.1% of patients with CKD- (p<0.0001). The most common in-hospital complication was the development of AKI (59.4%) in CKD+ versus 27% in CKD– patients (p<0.0001). CKD was associated with higher in-hospital and 30-day postdischarge mortality (both p<0.0001). Conclusions: The presence of CKD negatively impacts the prognosis of admitted patients with cirrhosis in a global cohort. Meticulous management of ascites and lifestyle changes, especially in HICs, may improve the outcome of these patients.


  • Machine Learning Models Using Hospital Admission Characteristics Do Not Optimally Predict Nosocomial Infection Development in a Global Cirrhosis Cohort

    by Scott Silvey, Ashok K. Choudhury, Patrick S. Kamath, Qing Xie, Florence Wong, Peter C. Hayes, Wai-Kay Seto, Umang Arora, Garima Singhal, Dinesh Jothimani, et al.

    INTRODUCTION: Nosocomial infections (NIs) in cirrhosis are associated with high mortality but could be preventable. Logistic regression (LR) models have failed to identify high-risk patients. We aimed to develop machine learning (ML) models to predict NI. METHODS: The CLEARED consortium consists of prospectively enrolled cirrhosis inpatients from >120 centers. Using day-of-admission clinical data, 3 ML approaches (random forest [RF], extreme gradient boosting, and neural networks [NNs]) were used to predict NI. Data were split 80:20 for training and testing stratified by the outcome. Models were compared using area under the receiver operating characteristic curve (AUC). RESULTS: In total, 8,263 patients (55.90 ± 13.34 years; 64.1% men) from 127 centers in 37 countries were included. NI developed in 869 (10.5%), a median of 6 (4–11) days of postadmission. Major NIs were respiratory (29.6%) and urinary tract infection (15.7%), and spontaneous bacterial peritonitis (13.5%). NIs occurred more frequently in patients from low/low-middle income countries and those with severe liver disease, alcohol etiology, and admission infections. NIs were associated with inpatient mortality (31.9% vs 8.1%, P < 0.001) and liver transplantation (4.8% vs 1.9%, P < 0.001). Although the RF model (AUC 0.69) showed good calibration (Brier score 0.09), outperforming extreme gradient boosting, neural network, and LR models (AUC 0.66 for all; LR comparison P = 0.043), no model achieved AUC ≥0.80 for clinical utility. At 10% predicted probability threshold, the RF model demonstrated only 75.4% sensitivity, 52.9% specificity, and 15.9% positive predictive value (PPV). DISCUSSION: NIs cannot be accurately predicted from day-of-admission data using ML models, even in a large, prospective, global cirrhosis cohort. Every hospitalized patient with cirrhosis should receive protocolized infection control measures.

  • Open Access

    Autoimmune hepatitis in children: Guidelines of the Indian Society of Pediatric Gastroenterology, Hepatology, and Nutrition (ISPGHAN)

    by Rajeev Khanna, Bikrant Bihari Lal, Vikrant Sood, Seema Alam, Aabha Nagral, Aathira Ravindranath, Aditi Kumar, Aniket Deshmukh, Anoop Saraya, Anshu Srivastava, et al.

    Autoimmune hepatitis (AIH) in children presents significant diagnostic and therapeutic challenges requiring a multidisciplinary and evidence-based approach. The Indian Society of Pediatric Gastroenterology, Hepatology, and Nutrition (ISPGHAN) convened a consensus meeting on February 23, 2025, bringing together national and international experts to address key clinical and research questions. The deliberations spanned epidemiology, clinical presentation, diagnosis including autoantibodies, immunoglobulin G (IgG), histology and diagnostic scores, therapeutic strategies, management of difficult-to-treat AIH, long-term monitoring, and special scenarios, such as seronegative AIH (SN-AIH), autoimmune sclerosing cholangitis/overlap syndromes and post-transplant complications like recurrence and de novo-AIH. Recommendations were formulated using standard GRADE system and finalized through structured consensus. These guidelines aim to standardize care, assist clinicians in decision-making, and improve outcomes in children with AIH across diverse healthcare settings.


  • Diabetes mellitus is linked to higher mortality in alcohol-related acute-on-chronic liver failure

    by Ashish Kumar, Anil Arora, Praveen Sharma, Rakhi Maiwall, Ashok Choudhury, Vinod Arora, Mohamed Rela, Dinesh Jothimani, Mamun A Mahtab, Harshad Devarbhavi, et al.

    Background Acute-on-chronic liver failure (ACLF) is a rapidly progressive syndrome marked by high short-term mortality. While diabetes mellitus (DM) is known to worsen liver-related outcomes, its specific impact on alcohol-related ACLF (ALD-ACLF) remains underexplored. This study aimed to assess the prognostic impact of DM on 90-day outcomes in ALD-ACLF using data from the APASL ACLF Research Consortium (AARC) database. Methods This observational study involved data from 5612 ACLF patients with documented 90-day outcomes. We identified 2096 patients with ALD-ACLF precipitated by alcoholic hepatitis. Patients with non-ALD etiologies, mixed etiologies, or non-alcoholic precipitants were excluded. Diabetic and non-diabetic patients were compared using 1:2 propensity score matching based on key baseline covariates. Survival outcomes were assessed using Kaplan–Meier analysis and multivariable Cox regression. Results After matching, 109 diabetic patients were compared with 218 well-matched non-diabetic controls. Diabetic patients had significantly lower overall survival (32 vs. 57%) and transplant-free survival (31 vs. 50%) compared to non-diabetics (log-rank p < 0.001). On multivariable Cox regression, DM was independently associated with increased 90-day mortality (HR 1.739, 95% CI 1.262–2.395, p < 0.001), along with elevated serum lactate (HR 1.187 per mmol/L, p < 0.001) and creatinine (HR 1.267 per mg/dL, p < 0.001). Conclusion Diabetes mellitus is a significant independent predictor of mortality in patients with ALD-ACLF. These findings highlight the need for early identification and integrated management of diabetes in ACLF care pathways to improve clinical outcomes.


  • Simvastatin Addition to Standard of Care Improves Long-Term Survival in Patients With Cirrhosis After Variceal Bleed: An Open Label Randomized Controlled Trial

    by Randeep Rana, Mohammed Tabish, Samagra Agarwal, Rajkumar Bayye, Syed Ahmed, Deepak Gunjan, Sanchit Sharma, Anoop Saraya

    INTRODUCTION: There is limited evidence about efficacy and safety of simvastatin in decompensated cirrhosis. We assessed whether addition of simvastatin to standard of care improves long-term survival in patients with cirrhosis after variceal bleeding. METHODS: This was a single-center open label randomized controlled trial with superiority design. Patients with cirrhosis (Child-Pugh score 5–12) were randomly assigned to receive either simvastatin (20 mg once-daily) (n = 130) or no drug (n = 138) in addition to standard therapy (carvedilol and band ligation) at day 5 of variceal bleeding episode. Primary outcome was all-cause mortality over 24-month follow-up. Secondary outcomes included individual complications of cirrhosis with death before decompensation as a competing event. RESULTS: Baseline characteristics were similar in both groups with a mean age of 45.0 ± 11.5 years and alcohol (48%) being the predominant etiology. Most patients were of Child-Pugh A (34%) and B (50%) stage. Twenty-four patients (18%) on simvastatin and 44 (31%) on standard therapy died over follow-up (hazard ratio [HR] for simvastatin: 0.48 [95% confidence interval 0.29–0.81]; P = 0.006) with similar results on intention to treat and on per-protocol analysis (excluding 17 patients who stopped simvastatin). Incidence of ascites (subdistributional HR [sHR]) 0.60 (0.39–0.92) and spontaneous bacterial peritonitis (sHR 0.30 [0.11–0.81]) was lower in the simvastatin arm. All cause decompensation (sHR 0.74 [0.52–1.05]), rebleeding (sHR 0.87 [0.57–1.34]), hepatic encephalopathy (sHR 0.71 [0.42–1.19]), and acute-on-chronic liver failure (sHR 0.65 [0.39–1.10]) were comparable in both arms. No heterogeneity of treatment effect was demonstrated across Child-Turcotte-Pugh class (P = 0.105) or etiology (P = 0.39). Incidence of serious adverse events was similar (43% in simvastatin and 52% in standard therapy, absolute risk difference: 9.1% [−2.9% to 21.0%]). DISCUSSION: Simvastatin may be associated with improved survival in selected patients with cirrhosis after variceal bleed and reduced incidence of new onset/refractory ascites and its complications (CTRI/2022/07/044263).


  • Adjunctive Incremental Pregabalin Therapy Leads to Better Pain Relief in Patients With Chronic Pancreatitis

    by Randeep Md Rana, Samagra Md Agarwal, Sumaira Msc Qamar, Srikanth Md Gopi, Renu Bhatia, Kumble Seetharama Madhusudhan, Deepak Md Gunjan, Anoop Md Saraya

    Objectives: Gabapentinoids like pregabalin have been inadequately explored in patients with painful chronic pancreatitis (CP) on a long-term basis. The objective was to study the pain relief on pregabalin as an adjunct therapy for 12 weeks in painful CP. Materials and Methods: In this double blind, randomized placebo-controlled trial, patients with painful CP with no ongoing inflammation(no pseudocyst/inflammatory head mass) or significant obstruction were randomized to receive either incremental doses of pregabalin or placebo for 12 weeks. The primary outcome was change in Izbicki pain score. Change in the quality of life (QoL) (SF-36 questionnaire), interference of pain with daily life [modified brief pain inventory- short form (mBPI-SF)] and patients’ global impression of change (PGIC) were assessed as secondary outcomes. Tolerability and adverse effects were noted as safety outcomes. As an exploratory outcome, the role of quantitative sensory testing (QST) to predict patients’ response to pregabalin was assessed. Results: Fifty-five patients with painful CP (age 29.9±10.6 y; 79% males; median illness duration 36 mo) were randomized to receive pregabalin (n=30) or placebo (n=25). Change in Izbicki pain score was significantly better in pregabalin group [pregabalin: −23.75 (IQR: −9.69 to −43.75) versus placebo: −8.75 (3.44 to −17.50); P =0.005]. Overall QoL and PGIC were also better and interference of pain with daily activities reduced in the pregabalin group [median change BPI severity pregabalin: −1.83 (−0.83 to −3.75) versus placebo: −0.67 (0.33 to −1.42); P =0.008; BPI interference pregabalin: −2.64 (−0.33 to −5.21) versus placebo: −0.43 (1.18 to −2.29); P =0.009]. Frequent adverse events included sleepiness (51.7%) and giddiness (58%) but drug discontinuation occurred in only 10.4% of patients. No QST parameters could predict pain response to pregabalin. Conclusions: Pregabalin is a useful adjunct to pain management in patients with CP.


  • Antibiotic prophylaxis to prevent infection in patients with Child–Pugh A cirrhosis with upper gastrointestinal bleed: an open label randomised controlled trial

    by Anany Gupta, Samagra Agarwal, Sanchit Sharma, Srikanth Gopi, Deepak Gunjan, Anoop Saraya

    Background and aims Although beneficial in reducing the risk of bacterial infections in patients with advanced decompensated cirrhosis after upper gastrointestinal (GI) bleed, the utility of prophylactic antibiotics in those with Child–Pugh A cirrhosis is not known. We studied if prophylactic antibiotics can be withheld in this cohort. Methods This was a single-centre, open-label randomised-controlled-trial with non-inferiority design. Patients of Child–Pugh A cirrhosis with upper-GI bleed and hemodynamic stability were randomised to receive either no prophylactic antibiotics (test-group) or ceftriaxone [standard of care (SOC)] for 72 h alongside standard medical management. The primary outcome was infection at day-5 in both arms. Secondary outcomes included failure to control bleed, mortality at day-5, and at 6 weeks. Results Eligible patients (n = 180; mean age 45.1 ± 13.1 years, 76.9% males; median MELDNa 9 [interquartile-range: 7–12]) of predominant non-viral etiology (alcohol: 43.4%; non-alcoholic steatohepatitis: 21.7%) were randomised, of whom outcomes could be reliably assessed for 172 and 140 patients at 5-day and 6-week follow-up, respectively. Rate of day-5 infections in test-group [7.0% (95% CI 2.8–15.1%)] was non-inferior to SOC arm [11.6% (95% CI 6.02–20.8%); absolute risk difference: −4.7% (95% CI −13.3% to 4.0%; non-inferior at 10% margin)]. Spontaneous bacterial peritonitis following post-bleed ascites was the most common site of infection in both groups (10/16; 66.7%). Rates of failure to control bleed [0% vs 4.9; absolute-risk-difference: −4.6% (95% CI −9.1% to 0.2%)], day-5 mortality [0% vs 2.5%; absolute-risk-difference: −2.3% (−5.5% to 0.9%)], and 6-week mortality [1.4% vs 2.5%; absolute-risk-difference: −1.6% (−6.5% to 3.2%)] were comparable in both arms. Conclusion Among patients with Child–Pugh A cirrhosis with hemodynamic stability, withholding prophylactic antibiotics after upper GI bleed was not associated with increased risk of post-bleed infections.


  • Open Access

    Epidemiology of chronic and acute pancreatitis in India (EPICAP-India): protocol for a multicentre study

    by Anand Krishnan, Divya Pillai, Ritvik Amarchand, Ashish Agarwal, Vineet Ahuja, Vineeta Baloni, Subhra Samujjwal Basu, Pankaj Bhardwaj, Bikash Choudhury, Sudipta Dhar Chowdhury, et al.

    Introduction Acute and chronic pancreatitis (CP) are inflammatory conditions of the pancreas that cause local and systemic complications. The epidemiology of these conditions are not well-known in India. Methods and analysis We describe the protocol and procedures of a multicentre study for delineating the epidemiology of pancreatitis in India. We plan to cover 110 000 people across 10 geographically distributed sites in 10 states of India to estimate the burden and risk factors of CP. Trained investigators will make house visits and screen for abdominal pain requiring hospitalisation or pre-diagnosed CP. The screened positive participants will be reviewed by a gastroenterologist to confirm the diagnosis of CP based on radiological imaging. For each case, four controls will be selected and data on risk factors for CP (tobacco, alcohol, family history, metabolic causes) and blood for genetic markers will be collected. Information on the cost of treatment and quality of life will be collected from patients with CP. For estimating incidence of acute pancreatitis (AP), hospital-based sentinel surveillance will be conducted in 10 districts across these 10 states. All hospitals in the district will be contacted to provide a line list of admissions due to acute abdomen including AP for 2 years. The spread of acute abdomen cases will be used to define the catchment area and estimate the denominator population. The line-listed cases with AP living in the catchment area will form the numerator to calculate the incidence. The study will provide critical information for planning pancreatitis-related services in the country. Ethics and dissemination The institutional ethics committee (IECs) at all the participating sites have given their approval for the study. All the participants whose data will be collected will be included after written informed consent. The results may be presented at national or international conferences and will be reported in peer-reviewed publications.